Literature DB >> 8659930

Relative prognostic importance of histologic invasion of the laryngeal framework by hypopharyngeal cancer.

F W Deleyiannis1, J F Piccirillo, J A Kirchner.   

Abstract

This study assessed the relative prognostic importance of histologic invasion of the laryngeal framework by hypopharyngeal cancer. The laryngeal specimens and medical records of 55 patients found to have primary hypopharyngeal cancer between 1962 and 1988 were reviewed. Full 3-year follow-up information was obtained for 51 patients. The overall 3-year survival rate was 43% A(22/51). The 3-year survival rate was 55% (17/31) without histologic invasion versus 25% (5/20) with invasion (p < .05). To assess how invasion affected survival rates in conjunction with clinical predictors, we divided the cohort into two groups (mild versus severe illness) based on the presence or absence of anemia and comorbidity. Only in the group with mild illness did histologic invasion provide additional prognostic information. These results demonstrate that the inclusion of clinical variables in predictions of prognosis can strikingly alter the prognostic importance of invasion of the laryngeal framework.

Entities:  

Mesh:

Year:  1996        PMID: 8659930     DOI: 10.1177/000348949610500204

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  2 in total

1.  Treatment results and prognostic factors of patients undergoing postoperative radiotherapy for laryngeal squamous cell carcinoma.

Authors:  Ting Jin; Wei-Han Hu; Li-Bing Guo; Wen-Kuan Chen; Qiu-Li Li; Hui Lin; Xiu-Yu Cai; Nan Ge; Rui Sun; Si-Yi Bu; Xin Zhang; Meng-Yao Qiu; Wei Zhang; Su Luo; Yi-Xin Zhou
Journal:  Chin J Cancer       Date:  2011-07

2.  Oncological and Functional Outcomes of Larynx-preserving Surgery for Hypopharyngeal Cancer: A Comparison with Definitive Radiation-based Treatment.

Authors:  Donghyeok Kim; Nalee Kim; Sungmin Koh; Man Ki Chung; Young-Ik Son; Dongryul Oh; Han-Sin Jeong; Yong Chan Ahn
Journal:  Cancer Res Treat       Date:  2021-03-26       Impact factor: 4.679

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.